6月2日，Abivax S.A.夜盘下跌25.58%，报96.51美元/股，成交额1.87万美元。消息面上，公司公布其核心药物obefazimod治疗中重度活动性溃疡性结肠炎的3期维持试验结果，虽然试验达到了主要终点，25mg和50mg两个剂量组亦满足相关目标，但市场对数据表现反应消极，股价在盘后大幅下挫。此前该股已从52周低点5.69美元大幅攀升至130美元上方，市场对试验数据的期望值已被充分定价，结果公布后出现获利了结压力。
Abivax S.A.是一家临床阶段生物技术公司，专注于开发利用人体自然调节机制稳定慢性炎症性疾病免疫反应的疗法，主要候选药物obefazimod正处于治疗溃疡性结肠炎的3期开发阶段，并正在开发用于克罗恩病。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.